KRAS and cancer: To broadly uncover the genetic interactions between tumor suppressor genes and these oncogenic KRAS variants in vivo, we generated barcoded Lenti-sgRNA/Cre vectors targeting 28 known and putative tumor suppressor genes that are recurrently mutated in human LUAD and represent key cancer pathways (Fig. 1A and Supplementary Fig. 2; “Methods”)21,26,30.